Q2 2024 Earnings Forecast for Alnylam Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Leerink Partnrs boosted their Q2 2024 EPS estimates for Alnylam Pharmaceuticals in a report issued on Tuesday, June 25th. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will earn ($0.90) per share for the quarter, up from their previous estimate of ($1.09). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($3.90) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q3 2024 earnings at ($0.91) EPS, Q4 2024 earnings at ($1.27) EPS, FY2024 earnings at ($3.61) EPS and FY2025 earnings at ($2.50) EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. The firm’s revenue was up 54.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.40) earnings per share.

Several other research firms also recently weighed in on ALNY. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 25th. SVB Leerink boosted their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. Citigroup raised their price target on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Barclays boosted their price objective on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a research report on Tuesday, June 25th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Eight equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $247.09.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $243.00 on Friday. The stock has a market capitalization of $30.74 billion, a P/E ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $252.87. The firm’s 50 day simple moving average is $159.86 and its two-hundred day simple moving average is $164.67.

Insiders Place Their Bets

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,357 shares of company stock worth $13,436,711. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Alnylam Pharmaceuticals by 8.1% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock valued at $4,964,000 after purchasing an additional 2,500 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter worth $238,000. Burney Co. grew its stake in shares of Alnylam Pharmaceuticals by 371.9% during the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock valued at $4,044,000 after purchasing an additional 21,325 shares during the period. Swedbank AB purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at approximately $3,084,000. Finally, Plato Investment Management Ltd increased its stake in shares of Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.